Eureka Therapeutics

March 24, 2021

Better late than never for Boehringer in Covid-19

Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.

August 17, 2020

With a following wind JW looks to go public

The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing.

December 03, 2018

Ash 2018 – Legend’s mystery CAR raises more questions

Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.

December 01, 2016

Triple meeting – Bluebird upstages its Ash rivals

September 19, 2016

Deal flurry shines spotlight on novel multiple myeloma target

August 08, 2016

Juno throws down the multiple myeloma gauntlet to Bluebird

January 08, 2016

Better late than never for Boehringer in Covid-19

With a following wind JW looks to go public

Ash 2018 – Legend’s mystery CAR raises more questions

Triple meeting – Bluebird upstages its Ash rivals

Deal flurry shines spotlight on novel multiple myeloma target

Juno throws down the multiple myeloma gauntlet to Bluebird

Juno and Kite follow Novartis to make CAR-T human

Latest Reports

Pharma Market Drivers Part Three: Blowin’ in the wind

Q3 Round Up: Alive but not kicking report

Editor's Picks

Lecanemab can; now the wait for details begins

The gloom deepens for biopharma stocks

SITC 2022 preview – cytokines and oral checkpoints

Big pharma’s key fourth-quarter data

TCT 2022 – Otsuka’s renal denervation system shines